This report was first published by Endpoints News. To see the original version, click here
Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup in a large upfront deal that also carries $1.05 billion in down-the-road potential.
Kali Therapeutics teamed with the French drug giant in a licensing pact worth $180 million in upfront and near-term payments. The tie-up centers around KT501, a trispecific TCE that goes after the well-known targets of CD19, BCMA and CD3.
您已阅读15%（568字），剩余85%（3292字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。